- 3QFY13 net profit miss of c10% on the back of higher expenses despite in line sales. Margin missed by c250bps
- Export formulations remain strong. India falls in line with market (4% below estimate) - growth guided at 15%
- Still evaluating Cipla Medpro offer. Downgrading to N from OW, revising TP to INR450 (from INR440), rolling to Dec-14e
